Abstract
High-resolution MRI of obese (fa/fa) Zucker rats was investigated to characterize and assess in vivo adipose tissue distribution. Thirty animals were gavaged with a placebo, a PPARγ activator (pioglitazone), or a dual PPARα γ activator (LM 4156). At day 15, T1-weighted images were acquired in vivo using a 2TMRI system with a high in-plane spatial resolution (254 μm). Fat volumes of selected territories were measured by image segmentation, and the retroperitoneal fat was weighed post-mortem. Body-weight gain was significant with pioglitazone (101.8±5.9 g, p<0.01 vs. placebo). The good quality of MR images allowed the delimitation and quantification of different fat territories. In response to pioglitazone, the retroperitoneal fat was more important compared to placebo (+23%, p<0.01) while subcutaneous fat was not different. No significant effects were observed with LM 4156. In vivo measurements of fat volumes were strongly correlated with ex vivo tissue weights (r=0.91). High-resolution MRI provides an in vivo measurement of adipose tissue distribution in obese Zucker rats. Specific fat depots of regions that were particularly involved in drug response were determined in vivo. Fat remodeling was observed with pioglitazone but not with a dual PPARα γ activator (LM 4156).
Similar content being viewed by others
References
Kirchengast S, Huber J (2004) Body composition characteristics and fat distribution patterns in young infertile women. Fertil Steril 81:539–544
Chan DC, Watts GF, Sussekov AV, Barrett PHR, Yang Z, Hua J, Song S (2004) Adipose tissue compartments and insulin resistance in overweight–obese Caucasian men. Diabetes Res Clin Pract 63:77–85
Changani KK, Nicholson A, White A, Latchman JK, Reid DG, Clapham JC (2003) A longitudinal magnetic resonance imaging (MRI) study of differences in abdominal fat distribution between normal mice, and lean overexpressors of mitochondrial uncoupling protein-3 (UCP-3). Diabetes Obes Metab 5:99–105
Tang H, Vasselli JR, Wu EX (2002) High-resolution magnetic resonance imaging tracks changes in organ and tissue mass in obese and aging rats. Am J Physiol Regul Comp Physiol 282:R890–R899
Kenneth JE (2000) Human body composition: in vivo methods. Physiol Rev 2:649–680
Yoshizumi T, Nakamura T, Yamane M, Islam AH, Menju M, Yamasaki K, Arai T, Kotani K, Funahashi T, Yamashita S, Matsuzawa Y (1999) Abdominal fat: standardized technique for measurement at CT. Radiology 211:283–286
Keller C, Chintapalli K, Lancaster J (1999) Correlation of anthropometry with CT in mexican-american women. Res Nurs Health 22:145–153
Lemieux S, Lesage M, Bergeron J, Prud’homme D, Després (1999) Comparison of two techniques for measurement of visceral adipose tissue cross-sectional areas by computed tomography. Am J Hum Biol 11:61–68
Paradisi G, Smith L, Burtner C, Leaming R, Gravey WT, Hook G, Johnson A, Cronin J, Steinberg HO, Baron AD (1999) Dual energy X-ray absorptiometry assessment of fat mass distribution and its association with the insulin resistance syndrome. Diabetes Care 22:1310–1317
Ross R (2003) Advances in the application of imaging methods in applied and clinical physiology. Acta Diabetol 40:S45–S50
Shen W, Wang Z, Punyanita M, Lei J, Sinav A, Kral JG, Imielinska C, Ross R, Heymsfield SB (2003) Adipose tissue quantification by imaging methods: a proposed classification. Obes Res 11:5–16
Ross R (1996) Magnetic resonance imaging provides new insights into the characterization of adipose and lean tissue distribution. Can J Physiol Pharmacol 74:778–785
Thomas EL, Saeed N, Hajnal JV, Brynes A, Goldstone AP, Frost G, Bell JD (1998) Magnetic resonance imaging of total body fat. J Appl Physiol 85:1778–1785
Gronemeyer SA, Steen RG, Kauffman WM, Reddick WE, Glass JO (2000) Fat adipose tissue (FAT) assessment by MRI. Magn Reson Imaging 18:815–818
Abate N, Burns D, Peshock RM, Garg A, Grundy SM (1994) Estimation of adipose tissue mass by magnetic resonance imaging: validation against dissection in human cadavers. J Lipid Res 35:1490–1496
Ishikawa M, Koga K (1998) Measurement of abdominal fat by magnetic resonance imaging of Oletf rats, an animal model of NIDDM. Magn Reson Imaging 16:45–53
Tintera J, Harantova P, Suchanek P, Dvorakova A, Adamova M, Hajek M, Poledne R (2004) Quantification of intra-abdominal fat during controlled weight reduction: assessment using the water-suppressed breath-hold MRI technique. Physiol Res 53:229–234
Olefsky JM, Saltiel AR (2000) PPAR gamma and the treatment of insulin resistance. Trends Endocrinol Metab 11:362–368
Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 270:12953–12956
Mori Y, Murakawa Y, Okada K, Horikoshi H, Yokoyama J, Tajima N, Ikeda Y (1999) Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care 22:908–912
Chaput E, Saladin R, Silvestre M, Edgar AD (2000) Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight. Biochem Biophys Res Commun 271:445–450
Chevreuil O, Contard F, Guerrier D (2003) LM 4156, a novel, balanced activator of PPAR alpha and gamma improves dyslipidemia in fa/fa Zucker Rats. Diabetes 52(Suppl. 6):A114
Contard F, Chevreuil O, Guerrier D (2003) LM 4156, a novel, balanced PPAR α and γ activator decreases hypertriglyceridaemia without effects on body weight and adipose tissue in fa/fa Zucker Rats. Diabetes 52(Suppl. 1):A444
Kelly IE, Han TS, Walsh K, Lean MEJ (1999) Effects of thiazolinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 22:288–293
De Souza CJ, Eckhardt M, Gagen K, Dong M, Chen W, Laurent D, Burkey BF (2001) effects of pioglitazone on adipose tissue remodelling within the setting of obesity and insulin resistance. Diabetes 50:1863–1871
Sinha R, Dufour S, Petersen KF, LeBon V, Enoksson S, et al. (2002) Assessment of skeletal muscle triglyceride content by 1H nuclear magnetic resonance spectroscopy in lean and obese adolescents. Diabetes 51:1022–1027
Jucker BM, Schaeffer TR, Haimbach RE, Mayer ME, Ohlstein EH, Smith SA, Cobitz AR, Susanta K Sarkar (2003) Reduction of intramyocellular lipid following short-term rosiglitazone treatment in Zucker fatty rats: an in vivo nuclear magnetic resonance study. Metabolism 52:218–225
Hallakou S, Doare L, Foufelle F, Kergoat M, Guerre-Millo M, Berthault MF, Dugail I, Morin J, Auwerx J, Ferre P (1997) Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Diabetes 46:1393–1399
Lebovitz HE (1997) Differentiating members of the thiazolidinedione class: a focus on safety. Diabetes Metab Res Rev 18(Suppl. 2):S23–S29
Tordjman J, Chauvet G, Quette J, Beale EG, Forest C, Antoine B (2003) Thiazolidinediones block fatty acid release by inducing glyceroneogenesis in fat cells. The J Biol Chem 278:18785–18790
Lebovitz HE (2003) The relationship of obesity to the metabolic syndrome. Int J Clin Pract Suppl 134:18–27
Wajchenberg BL (2000) Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 21(6):697–738
Oakes ND, Thalen PG, Jacinto SM, Ljung B (2001) Thiazolidinediones increase plasma adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability. Diabetes 50:1158–1165
Lebovitz HE (1997) Differentiating members of the thiazolidinedione class: a focus on safety. Diabetes Metab Res Rev 18(Suppl. 2):S23–S29
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fissoune, R., Pellet, N., Chaabane, L. et al. Evaluation of adipose tissue distribution in obese fa/fa Zucker rats by in vivo MR imaging: effects of peroxisome proliferator-activated receptor agonists. MAGMA 17, 229–235 (2004). https://doi.org/10.1007/s10334-004-0088-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10334-004-0088-y